Moderna, Inc. $MRNA Stock Position Lifted by Retirement Systems of Alabama

Retirement Systems of Alabama increased its position in Moderna, Inc. (NASDAQ:MRNA) by 5.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,862 shares of the company’s stock after buying an additional 3,678 shares during the quarter. Retirement Systems of Alabama’s holdings in Moderna were worth $14,994,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. BlackRock Inc. bought a new stake in Moderna in the 2nd quarter worth $2,142,877,000. Theleme Partners LLP purchased a new position in shares of Moderna in the second quarter valued at about $564,272,000. Merck & Co. Inc. bought a new position in shares of Moderna during the second quarter valued at about $161,642,545. Bamco Inc. NY bought a new position in shares of Moderna during the second quarter valued at about $139,317,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Moderna during the second quarter valued at about $119,168,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Down 7.0%

Shares of NASDAQ MRNA opened at $231.35 on Friday. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80. The firm has a market capitalization of $93.61 billion, a PE ratio of -32.58 and a beta of 1.16. The firm has a fifty day simple moving average of $200.18 and a two-hundred day simple moving average of $95.52.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. Equities analysts expect that Moderna, Inc. will post -5.34 earnings per share for the current year.

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the transaction, the president owned 1,525,858 shares in the company, valued at $219,921,913.54. This trade represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock valued at $33,875,904 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on MRNA. Singular Research raised Moderna to a “hold” rating in a research note on Wednesday, September 23rd. Morgan Stanley boosted their price target on Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Bank of America upped their price target on Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Jefferies Financial Group reiterated a “hold” rating and issued a $150.00 price objective (up from $60.00) on shares of Moderna in a report on Wednesday, August 19th. Finally, Rothschild & Co Redburn lowered Moderna from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $40.00 to $81.00 in a research report on Thursday, September 3rd. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $113.75.

Moderna News Roundup

Investors following MRNA have been watching these news items:

• Positive Sentiment: The company reported peer-reviewed real-world data on mNEXSPIKE in adults aged 65 and older, based on an analysis of more than 294,000 U.S. veterans. The findings may help support the vaccine’s commercial position. Moderna is also scheduled to join the MSCI World Index in November, potentially broadening its investor visibility. Article: Moderna Index Inclusion and Vaccine Data
• Negative Sentiment: Investors focused on the cost of that strategy: Moderna expects about $4 billion in cash costs in 2027. The planned investment raises the stakes for its cancer programs and could prolong the path to profitability. Article: Moderna Analyst Day Spending
• Negative Sentiment: Despite the raised forecast, coverage noted that Moderna’s 2026 revenue outlook may still be below analyst expectations, fueling concern about a potential sales shortfall. That outlook, combined with elevated investment needs, appears to have outweighed the positive updates. Article: Why Moderna Stock Dropped

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.